IL196672A0 - Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders - Google Patents

Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders

Info

Publication number
IL196672A0
IL196672A0 IL196672A IL19667209A IL196672A0 IL 196672 A0 IL196672 A0 IL 196672A0 IL 196672 A IL196672 A IL 196672A IL 19667209 A IL19667209 A IL 19667209A IL 196672 A0 IL196672 A0 IL 196672A0
Authority
IL
Israel
Prior art keywords
treatment
related disorders
benzimidazole derivatives
derivatives useful
receptor trpv1
Prior art date
Application number
IL196672A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Brown William
Labrecque Denis
Johnstone Shawn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL196672(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Brown William, Labrecque Denis, Johnstone Shawn filed Critical Astrazeneca Ab
Publication of IL196672A0 publication Critical patent/IL196672A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL196672A 2006-08-11 2009-01-22 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders IL196672A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83724906P 2006-08-11 2006-08-11
PCT/SE2007/000720 WO2008018827A1 (en) 2006-08-11 2007-08-10 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders

Publications (1)

Publication Number Publication Date
IL196672A0 true IL196672A0 (en) 2009-11-18

Family

ID=39033277

Family Applications (1)

Application Number Title Priority Date Filing Date
IL196672A IL196672A0 (en) 2006-08-11 2009-01-22 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders

Country Status (25)

Country Link
US (2) US7906654B2 (enExample)
EP (1) EP2051967B1 (enExample)
JP (1) JP5140077B2 (enExample)
KR (1) KR101412881B1 (enExample)
CN (2) CN101522637A (enExample)
AR (1) AR062299A1 (enExample)
AU (1) AU2007282186B2 (enExample)
BR (1) BRPI0715746B8 (enExample)
CA (1) CA2660529C (enExample)
CL (1) CL2007002343A1 (enExample)
CO (1) CO6150176A2 (enExample)
ES (1) ES2533971T3 (enExample)
IL (1) IL196672A0 (enExample)
MX (1) MX2009001496A (enExample)
MY (1) MY147649A (enExample)
NO (1) NO20091054L (enExample)
NZ (1) NZ575416A (enExample)
PE (1) PE20081315A1 (enExample)
RU (1) RU2458055C2 (enExample)
SG (1) SG173360A1 (enExample)
TW (1) TWI433839B (enExample)
UA (1) UA96764C2 (enExample)
UY (1) UY30533A1 (enExample)
WO (1) WO2008018827A1 (enExample)
ZA (1) ZA200900961B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2264031B1 (en) 2008-04-18 2015-04-15 Daewoong Pharmaceutical Co., Ltd. A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
KR102546020B1 (ko) 2014-12-08 2023-06-20 롬 앤드 하아스 컴패니 폴리올레핀 첨가제, 처짐 저항성 폴리올레핀 및 이를 제조하는 방법
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
EP3908574A4 (en) * 2019-01-08 2022-10-26 Neomed Institute CRYSTALLINE FORMS OF (S)-2-(7-CYANO-1H-BENZIMIDAZOL-1YL)-N-{1-[4-(1-CYANO-1-METHYLETHYL)PHENYL]ETHYL}ACETAMIDE
US12370192B2 (en) 2019-09-16 2025-07-29 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN117623972A (zh) * 2022-08-17 2024-03-01 上海慧聚药业有限公司 非离子型造影剂中间体的合成

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
BE793718A (fr) 1972-01-07 1973-07-05 Merck & Co Inc Aminobenzimidazoles
DE3347290A1 (de) 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4738981A (en) * 1984-11-13 1988-04-19 Warner-Lambert Substituted trans-1,2-diaminocyclohexyl amide compounds
JP2639000B2 (ja) 1988-09-30 1997-08-06 スズキ株式会社 酸素富化エンジンの酸素富化空気制御装置
JPH0295767A (ja) 1988-09-30 1990-04-06 Showa Alum Corp 吸気マニホルド
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
IL124969A (en) 1995-12-28 2002-09-12 Fujisawa Pharmaceutical Co History of benzimidazole, processes for their preparation and pharmaceutical preparations containing them
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
HK1050008A1 (zh) 2000-05-05 2003-06-06 Portola Pharmaceuticals, Inc. 杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2420042A1 (en) 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
ITTO20010110A1 (it) 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
US7144883B2 (en) 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
WO2003014064A1 (en) 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP4059473B2 (ja) * 2001-08-09 2008-03-12 株式会社ルネサステクノロジ メモリカード及びメモリコントローラ
PE20030417A1 (es) 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
EP1463714A4 (en) 2001-12-10 2005-10-19 Amgen Inc VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
JP2005526723A (ja) 2002-02-15 2005-09-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーター
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CN1662521A (zh) 2002-06-20 2005-08-31 比奥维特罗姆股份公司 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
FR2842069B1 (fr) * 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
OA13248A (en) 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Also Published As

Publication number Publication date
MY147649A (en) 2012-12-31
WO2008018827A8 (en) 2009-02-19
NZ575416A (en) 2011-10-28
CL2007002343A1 (es) 2008-04-04
TW200817338A (en) 2008-04-16
WO2008018827A1 (en) 2008-02-14
JP5140077B2 (ja) 2013-02-06
US8093402B2 (en) 2012-01-10
CN101522637A (zh) 2009-09-02
US20080221188A1 (en) 2008-09-11
AR062299A1 (es) 2008-10-29
CA2660529A1 (en) 2008-02-14
US20110137045A1 (en) 2011-06-09
CO6150176A2 (es) 2010-04-20
BRPI0715746B8 (pt) 2021-05-25
AU2007282186B2 (en) 2011-07-07
RU2009103675A (ru) 2010-09-20
ZA200900961B (en) 2010-07-28
SG173360A1 (en) 2011-08-29
KR20090035701A (ko) 2009-04-10
RU2458055C2 (ru) 2012-08-10
MX2009001496A (es) 2009-02-18
UY30533A1 (es) 2008-03-31
KR101412881B1 (ko) 2014-06-26
CN101792436A (zh) 2010-08-04
US7906654B2 (en) 2011-03-15
ES2533971T3 (es) 2015-04-16
EP2051967A4 (en) 2011-06-29
CA2660529C (en) 2014-10-21
UA96764C2 (ru) 2011-12-12
EP2051967A1 (en) 2009-04-29
BRPI0715746A2 (pt) 2013-07-16
BRPI0715746B1 (pt) 2020-09-24
AU2007282186A1 (en) 2008-02-14
JP2010500345A (ja) 2010-01-07
PE20081315A1 (es) 2008-11-08
EP2051967B1 (en) 2014-12-31
TWI433839B (zh) 2014-04-11
NO20091054L (no) 2009-03-09

Similar Documents

Publication Publication Date Title
IL196672A0 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
ZA200806457B (en) Use of 4-imidazole derivatives for CNS disorders
ZA201004227B (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL200639A0 (en) Benzimidazole derivatives and methods of use thereof
PL2102169T3 (pl) Amidowe pochodne indazolilu do leczenia zaburzeń pośredniczonych receptorem glukokortykoidowym
GB0703909D0 (en) Treatment of anxiety disorders
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL206880A0 (en) Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
ZA201004134B (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
IL198334A0 (en) 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
EP2099444A4 (en) USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
GB0725077D0 (en) Antifolate com[ounds for the treatment of melanoma
HK1130257A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
GB0619218D0 (en) Treatment of conformational disorders
ZA200810373B (en) Piperazinyl derivatives useful in the treatment of GPR38 receptor mediated diseases